Treatment of Severe Cancer Pain by Transdermal Fentanyl

Overview

Journal Bosn J Basic Med Sci

Specialty General Medicine

Date 2010 May 29

PMID 20507298

Authors

Dzenita Ljuca

Samir Husic

Affiliations

Soon will be listed here.

Abstract

The goal of research was to determine the frequency, intensity, time of occurrence, duration and causes of breakthrough pain (BTP) in patients whose carcinoma pain was treated by transdermal fentanyl. (TDF). A prospective study was conducted in a hospice for recumbent patients of the Centre for Palliative Care (hospice) University Clinical Centre Tuzla from October 2009 to December 2010. 33 patients in terminal stage of carcinoma, who had been treated by transdermal fentanyl due to their excruciating pain (7-10 mark on numerical scale) with initial dosage of 25 microg as a strong opiate analgesic, were monitored within the time period of 10 days. In the statistics we used the even T - test, the Wilcox test and Mann-Whitney test. The difference was seen to be significant at p < 0.05. Treatment by transdermal fentanyl significantly reduces the intensity of strong carcinoma pain (p < 0.0001), with a frequent requirement for dose increase with bone metastasis. The intensity of BTP is higher compared to the pain experienced upon reception. The frequency and intensity of BTP are significantly reduced already in the second day of treatment by transdermal fentanyl (p = 0.0024). The BTP is most intense in patients with neck and head tumours (9.26 +/- 0.66), and most frequent with abdomen and pelvic tumour. The biggest number of BTP (68.3 %) occurs within first three days of treatment. BTP most frequently occurs in the evening or at night (between 18:00 and 06:00 h in 62.2 % of the cases), with the duration of usually less than 15 minutes (65.2 % of the cases). In 61.6 % cases the occurrence of BTP is related to physical activities or psychosocial incidents, while the cause is undetermined in 38.4 % of examinees. BTP is most frequent within first three days of treatment by TDF. Using the optimal dosage a good control of carcinoma pain is enabled, regardless of the occurrence of bone metastasis, while it also helps reduce the frequency and intensity of BTP.

References

Wincent A, Liden Y, Arner S . Pain questionnaires in the analysis of long lasting (chronic) pain conditions. Eur J Pain. 2003; 7(4):311-21. DOI: 10.1016/S1090-3801(03)00044-2. View

Weiss S, Emanuel L, Fairclough D, Emanuel E . Understanding the experience of pain in terminally ill patients. Lancet. 2001; 357(9265):1311-5. DOI: 10.1016/S0140-6736(00)04515-3. View

Korte W, Morant R . Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients. Support Care Cancer. 1994; 2(2):123-7. DOI: 10.1007/BF00572094. View

Gomez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M . Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002; 24(1):45-52. DOI: 10.1016/s0885-3924(02)00421-9. View

Payne R . Recognition and diagnosis of breakthrough pain. Pain Med. 2007; 8 Suppl 1:S3-7. DOI: 10.1111/j.1526-4637.2006.00269.x. View

Seccareccia D . Pain patch. Can Fam Physician. 2007; 53(9):1447-8. PMC: 2234622. View

Hwang S, Chang V, Kasimis B . Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003; 101(1-2):55-64. DOI: 10.1016/s0304-3959(02)00293-2. View

Mantyh P, Clohisy D, Koltzenburg M, Hunt S . Molecular mechanisms of cancer pain. Nat Rev Cancer. 2002; 2(3):201-9. DOI: 10.1038/nrc747. View

Watkins L, Maier S . Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002; 82(4):981-1011. DOI: 10.1152/physrev.00011.2002. View

10.

Delaney A, Fleetwood-Walker S, Colvin L, Fallon M . Translational medicine: cancer pain mechanisms and management. Br J Anaesth. 2008; 101(1):87-94. DOI: 10.1093/bja/aen100. View

11.

Zeppetella G, ODoherty C, Collins S . Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000; 20(2):87-92. DOI: 10.1016/s0885-3924(00)00161-5. View

12.

Mystakidou K, Befon S, Tsilika E, Dardoufas K, Georgaki S, Vlahos L . Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Oncology. 2002; 62(1):9-16. DOI: 10.1159/000048241. View

13.

Portenoy R, Hagen N . Breakthrough pain: definition, prevalence and characteristics. Pain. 1990; 41(3):273-281. DOI: 10.1016/0304-3959(90)90004-W. View

14.

Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F . Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002; 94(3):832-9. DOI: 10.1002/cncr.10249. View

15.

Svendsen K, Andersen S, Arnason S, Arner S, Breivik H, Heiskanen T . Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005; 9(2):195-206. DOI: 10.1016/j.ejpain.2004.06.001. View

16.

Zeppetella G . Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage. 2008; 35(5):563-7. DOI: 10.1016/j.jpainsymman.2007.06.012. View